Cardiac Pacing • Research Questions

LBBAP vs. Bicameral Leadless Pacemaker — Key Scientific Questions

This mini‑review frames five research‑grade questions to guide study design and clinical decision‑making when choosing between Left Bundle Branch Area Pacing (LBBAP) and dual‑chamber leadless pacemaker systems.

Clinical Context

Choosing between conduction system pacing (e.g., LBBAP) and bicameral leadless pacing involves balancing electrical synchrony, procedural risk, venous/lead considerations, and device longevity. The questions below are structured to be testable in prospective cohorts or pragmatic trials and to map onto endpoints that matter for patients and systems of care.

Five Research‑Grade Questions

Hemodynamic Optimization.
How do acute and chronic hemodynamic parameters (LV dP/dt_max, stroke volume, LV global longitudinal strain, and mechanical synchrony by speckle‑tracking) compare between LBBAP and dual‑chamber leadless pacing?
Conduction Integrity & Remodeling.
What are the long‑term effects on QRS duration, LV activation time, and ventricular remodeling indices (LVEDV, LVEF, scar progression by CMR) for LBBAP vs. bicameral leadless pacing, and how do these relate to heart‑failure hospitalizations and atrial/ventricular arrhythmias?
Energy Efficiency & Device Longevity.
How do capture thresholds, sensing stability, duty cycles, and battery use (including atrial‑ventricular communication overhead in leadless systems) diverge over multi‑year follow‑up?
Patient Selection & Outcomes.
In which clinical subsets (sinus‑node dysfunction, high‑grade AV block, CRT‑indicated patients not amenable to CS lead, HFpEF/HFrEF) does LBBAP deliver superior composite outcomes (death/HF admission/AF burden) compared with bicameral leadless pacing?
Safety, Procedural Risk & Retrievability.
What are the comparative rates of acute complications (septal perforation, embolization, pericardial effusion), chronic complications (infection, threshold rise, septal fibrosis), and successful retrieval/revision for LBBAP vs. dual‑chamber leadless pacing?

Suggested Study Designs

Prospective multicenter cohort with time‑to‑event analysis; optional randomization where feasible.
Core lab adjudication for ECG/echo/CMR endpoints; blinded analysis of strain and activation metrics.
Device interrogation schedule: implantation, 1, 3, 6, 12 months, then every 6–12 months.

Primary/Secondary Endpoints

Primary: Composite of all‑cause mortality, HF hospitalization, or ≥10% drop in LVEF at 24 months.
Key Secondary: QRS duration change, LA volume index, AF burden, 6‑minute walk distance, KCCQ, capture thresholds, battery longevity model.

Practical Decision Framework

Anatomy & Access: Venous occlusion, prior device infection, dialysis catheters → consider leadless options; septal substrate suitable for LBBAP → favor conduction system pacing.
Electrical Goals: Need for physiologic activation (bundle capture) or resynchronization → favor LBBAP; need for atrial sensing/pacing with AV timing but no leads → favor bicameral leadless.
Comorbidity & Risk: High infection risk or limited venous access → leadless advantage; septal fibrosis or high capture thresholds → may reduce LBBAP durability.
Follow‑up Logistics: Anticipated MRI/CMR needs, retrieval feasibility, and clinic/device‑clinic infrastructure.

Minimal Reporting Set (for publications)

Exact LBBAP criteria (LBBA vs. LBB capture confirmation, ECG criteria) and fluoroscopy/ICE use.
Leadless system model(s), atrial‑ventricular communication method, and programmed AV delays.
Thresholds/sensing at implant and follow‑up, QRS & activation metrics, echo/CMR protocol.
Device longevity modeling assumptions and explant/retrieval policies.

Notes & References

This page intentionally avoids citing specific trials to keep it evergreen. For publication, insert guideline statements (HRS/EHRA/APHRS/LAHRS on physiologic pacing), landmark LBBAP multicenter registries, and the latest leadless dual‑chamber trial data in this section.